What is HC Wainwright’s Forecast for ORIC Q1 Earnings?

Oric Pharmaceuticals, Inc. (NASDAQ:ORIC) – Investment analysts at HC Wainwright issued their Q1 2027 earnings per share estimates for Oric Pharmaceuticals in a report released on Monday, August 10th. HC Wainwright analyst R. Burns expects that the company will earn ($0.43) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $27.00 target price on the stock. The consensus estimate for Oric Pharmaceuticals’ current full-year earnings is ($1.51) per share. HC Wainwright also issued estimates for Oric Pharmaceuticals’ Q2 2027 earnings at ($0.45) EPS and FY2027 earnings at ($1.85) EPS.

Oric Pharmaceuticals (NASDAQ:ORIC) last issued its earnings results on Monday, August 3rd. The company reported ($0.38) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.36) by ($0.02).

ORIC has been the subject of several other reports. Benchmark reaffirmed a “buy” rating on shares of Oric Pharmaceuticals in a report on Monday, June 8th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Oric Pharmaceuticals in a research report on Friday, May 22nd. Stifel Nicolaus initiated coverage on Oric Pharmaceuticals in a research note on Friday, June 12th. They set a “buy” rating and a $14.00 price target for the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Oric Pharmaceuticals in a report on Friday, July 17th. Finally, Wall Street Zen upgraded Oric Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Saturday, July 25th. Thirteen analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $19.45.

Oric Pharmaceuticals Stock Performance

Shares of NASDAQ ORIC opened at $13.62 on Tuesday. The stock has a market cap of $1.41 billion, a price-to-earnings ratio of -10.09 and a beta of 1.02. Oric Pharmaceuticals has a fifty-two week low of $7.23 and a fifty-two week high of $14.93. The firm’s 50-day simple moving average is $10.24 and its 200 day simple moving average is $10.47.

Institutional Trading of Oric Pharmaceuticals

Hedge funds have recently modified their holdings of the business. Federation des caisses Desjardins du Quebec lifted its position in Oric Pharmaceuticals by 100.0% during the fourth quarter. Federation des caisses Desjardins du Quebec now owns 4,000 shares of the company’s stock valued at $33,000 after purchasing an additional 2,000 shares during the period. Caitong International Asset Management Co. Ltd increased its position in Oric Pharmaceuticals by 184.4% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 4,528 shares of the company’s stock valued at $37,000 after acquiring an additional 2,936 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its holdings in Oric Pharmaceuticals by 26.0% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,732 shares of the company’s stock valued at $39,000 after acquiring an additional 977 shares during the period. Russell Investments Group Ltd. bought a new stake in shares of Oric Pharmaceuticals during the 3rd quarter valued at about $60,000. Finally, CANADA LIFE ASSURANCE Co purchased a new stake in shares of Oric Pharmaceuticals during the 3rd quarter valued at about $65,000. Institutional investors own 95.05% of the company’s stock.

About Oric Pharmaceuticals

Oric Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company headquartered in South San Francisco, California. The firm is dedicated to discovering and developing small molecule therapeutics designed to overcome resistance mechanisms in solid tumor oncology. Its research efforts focus on identifying novel targets and advancing precision medicines that can restore or enhance patient response when standard therapies fail.

The company’s pipeline features lead candidates such as ORIC-101, a selective, orally available antagonist of the glucocorticoid receptor currently being evaluated in Phase 1/2 trials for patients with solid tumors who have acquired resistance to chemotherapy and hormonal agents.